Keros Therapeutics (NASDAQ:KROS) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a strong sell rating in a report released on Saturday morning,Wall Street Zen reports.

KROS has been the subject of a number of other research reports. Zacks Research upgraded Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 27th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Leerink Partners reduced their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. Finally, Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Keros Therapeutics currently has an average rating of “Hold” and an average price target of $20.50.

Keros Therapeutics Stock Up 0.4%

Shares of NASDAQ KROS opened at $11.33 on Friday. The stock has a fifty day moving average price of $11.20 and a 200 day moving average price of $12.32. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. As a group, sell-side analysts expect that Keros Therapeutics will post -5.27 EPS for the current fiscal year.

Keros Therapeutics declared that its board has approved a share repurchase program on Wednesday, September 9th that allows the company to repurchase $5 million in outstanding shares. This repurchase authorization allows the company to buy up to 2.3% of its shares through open market purchases. Share repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the transaction, the insider owned 27,559 shares of the company’s stock, valued at $283,582.11. This trade represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 5,343 shares of company stock worth $54,985. 12.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently made changes to their positions in KROS. Caitong International Asset Management Co. Ltd increased its position in Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares during the period. Legal & General Group Plc acquired a new position in Keros Therapeutics during the 2nd quarter worth $90,000. PDT Partners LLC bought a new position in shares of Keros Therapeutics in the second quarter worth $122,000. Lazard Asset Management LLC bought a new position in shares of Keros Therapeutics in the first quarter worth $129,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of Keros Therapeutics in the second quarter worth $247,000. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.